Literature DB >> 28211264

Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation.

A Casini1, T Brungs2, C Lavenu-Bombled2, R Vilar3, M Neerman-Arbez3, P de Moerloose1.   

Abstract

Essentials Hypodysfibrinogenemia is rarely reported among the congenital fibrinogen disorders. This first systematic literature review led to identification of 51 hypodysfibrinogenemic cases. Diagnosis based only on functional/antigenic fibrinogen ratio may be insufficient. Family studies show an incomplete segregation of mutation with the clinical phenotypes.
SUMMARY: Background Hypodysfibrinogenemia is a rare disease characterized by decreased levels of a dysfunctional fibrinogen. It shares features with both hypo- and dysfibrinogenemia, although with specific molecular patterns and clinical phenotypes. Objectives To better define the genetics, the diagnosis and the clinical features of hypodysfibrinogenemia. Patients/Methods A systematic literature search led to 167 records. After removal of duplicates, abstract screening and full-text reviewing, 56 molecular and/or clinical studies were analyzed, including a novel FGB missense mutation in a woman with a mild bleeding phenotype. Results A total of 32 single causative mutations were reported, mainly in the COOH-terminal region of the γ or Aα chains at heterozygous or homozygous state. Seven additional hypodysfibrinogenemias were due to compound heterozygosity. The hypofibrinogenemic phenotypes were a result of an impaired assembly or secretion or an increased clearance of the fibrinogen variant, whereas the dysfibrinogenemic phenotype was mainly a result of a defective fibrin polymerization and an abnormal calcium or tPA binding. Among 51 identified index cases, a functional/antigenic fibrinogen ratio < 0.7 had a sensitivity of 86% for the diagnosis of hypodysfibrinogenemia. Eleven patients (22%) were asymptomatic at time of diagnosis, 23 (45%) had a mild bleeding phenotype with mainly obstetrical or gynecologic-related hemorrhage and 22 (43%) had experienced at least one thrombotic event, including 23 venous and eight arterial thromboses. Conclusions This first systematic review on hypodysfibrinogenemia shows the heterogeneity of causative mutations and that misdiagnosis could occur in relation to the functional and antigenic fibrinogen levels. Family studies reveal an incomplete segregation of the mutation with the clinical phenotype.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding; congenital; fibrinogen; hypodysfibrinogenemia; hypofibrinogenemia; mutation; thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28211264     DOI: 10.1111/jth.13655

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

1.  Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.

Authors:  Elena Chinni; Giovanni Tiscia; Giovanni Favuzzi; Filomena Cappucci; Giuseppe Malcangi; Rossana Bagna; Claudia Izzi; Domenica Rizzi; Valerio De Stefano; Elvira Grandone
Journal:  Blood Transfus       Date:  2018-10-08       Impact factor: 3.443

2.  Novel variant fibrinogen γp.C352R produced hypodysfibrinogenemia leading to a bleeding episode and failure of infertility treatment.

Authors:  Masahiro Yoda; Takahiro Kaido; Tomu Kamijo; Chiaki Taira; Yumiko Higuchi; Shinpei Arai; Nobuo Okumura
Journal:  Int J Hematol       Date:  2021-06-12       Impact factor: 2.490

3.  Congenital hypodysfibrinogenemia associated with a novel deletion of three residues (γAla289_Asp291del) in fibrinogen.

Authors:  Liqing Zhu; Misheng Zhao; Mingshan Wang; Zhefeng Lou; Xiaoli Chen; Liangliang Pan; Dandan Yu; Wenli Xia; Han Wang; Bin Zhou; Shenmeng Gao
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

4.  A novel fibrinogen mutation: FGA g. 3057 C > T (p. Arg104 > Cys) impairs fibrinogen secretion.

Authors:  R Marchi; M Linares; H Rojas; A Ruiz-Sáez; M Meyer; A Casini; S O Brennan
Journal:  BMC Hematol       Date:  2017-12-22

Review 5.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

Review 6.  Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.

Authors:  Tomas Simurda; Monika Brunclikova; Rosanna Asselta; Sonia Caccia; Jana Zolkova; Zuzana Kolkova; Dusan Loderer; Ingrid Skornova; Jan Hudecek; Zora Lasabova; Jan Stasko; Peter Kubisz
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

Review 7.  Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders.

Authors:  Giovanni Luca Tiscia; Maurizio Margaglione
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

8.  Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: Observational study of efficacy and safety for prophylaxis and treatment.

Authors:  Joseph Lasky; Jerome Teitel; Michael Wang; Danielle Dalton; Dirk Steffen Schmidt; Andres Brainsky
Journal:  Res Pract Thromb Haemost       Date:  2020-10-11

9.  Whole Blood Thromboelastometry by ROTEM and Thrombin Generation by Genesia According to the Genotype and Clinical Phenotype in Congenital Fibrinogen Disorders.

Authors:  Timea Szanto; Riitta Lassila; Marja Lemponen; Elina Lehtinen; Marguerite Neerman-Arbez; Alessandro Casini
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

10.  Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.

Authors:  Réka Gindele; Adrienne Kerényi; Judit Kállai; György Pfliegler; Ágota Schlammadinger; István Szegedi; Tamás Major; Zsuzsanna Szabó; Zsuzsa Bagoly; Csongor Kiss; János Kappelmayer; Zsuzsanna Bereczky
Journal:  Life (Basel)       Date:  2021-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.